Results 11 to 20 of about 16,167 (200)
Терапевтический архив, 2015 Mineralocorticoid receptor antagonists (MCRA) are part of standard medical therapy for heart failure (HF). The clinical efficacy of MCRA in patients with systolic HF has been proven by randomized clinical trials.
Yu F Osmolovskaya +2 more
doaj +1 more source
Mineralocorticoid Receptor Antagonists [PDF]
International Cardiovascular Forum Journal, 2019 Two mineralocorticoid receptor antagonists, spironolactone and eplerenone, are currently approved by the FDA. Several non-steroid based ligands are in clinical trials for indications including heart failure, hypertension and diabetic kidney disease, and even more structurally distinct chemical series are reported in the literature with preclinical data
Anneli, Nordqvist, Kenneth L, Granberg
+5 more sources
Mineralocorticoid Receptor Antagonists in ESKD [PDF]
Clinical Journal of the American Society of Nephrology, 2020 There is an urgent need for interventions that reduce cardiovascular risks in patients with ESKD. Recently there has been considerable interest in whether blocking the effects of the mineralocorticoid aldosterone could be such an intervention.
Adhish, Agarwal, Alfred K, Cheung
openaire +2 more sources
Thiazides and mineralocorticoid receptor antagonists in chronic kidney disease [PDF]
Romanian Journal of Medical Practice, 2022 The latest treatment guidelines for patients with arterial hypertension continues to indicate as the first line therapy a minimal association between renin-angiotensin system (RAS) blockers and a thiazide-type or a thiazide-like diuretic.
Andrei Niculae +5 more
doaj +1 more source
Vascular cell‐specific roles of mineralocorticoid receptors in pulmonary hypertension
Pulmonary Circulation, 2021 Abnormalities that characterize pulmonary arterial hypertension include impairment in the structure and function of pulmonary vascular endothelial and smooth muscle cells.
Divya P. Menon +10 more
doaj +1 more source
Mineralocorticoid Receptor Antagonists Mitigate Mitral Regurgitation-Induced Myocardial Dysfunction
Cells, 2022 Mitral regurgitation (MR), the disruption of the mitral valve, contributes to heart failure (HF). Under conditions of volume overload, excess mineralocorticoids promote cardiac fibrosis.
Wei-Ting Chang +7 more
doaj +1 more source
New Therapies on the Horizon for Preventing the Progression of Chronic Kidney Disease in Childhood
Çocuk Dergisi, 2023 The purpose of the review is to summarize the current pharmacological management of chronic kidney disease (CKD) in pediatric patients and critically present emerging evidence for the use of mineralocorticoid receptor antagonists and sodium-glucose ...
Siobhan Wagner +2 more
doaj +1 more source
PATIENT WITH CHRONIC HEART FAILURE. RATIONAL CHOICE OF THERAPY
Рациональная фармакотерапия в кардиологии, 2017 The theory of chronic hyperactivation of neurohormonal systems, in particular, sympathoadrenal and renin-angiotensin-aldosterone, is the basis of modern concepts of the pathogenesis of heart failure. The medicinal blocking of these two systems has proved
O. M. Drapkina, D. U. Akasheva
doaj +1 more source
Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, 2022 Background Guideline‐recommended disease‐modifying pharmacological therapies for heart failure (HF) with reduced ejection fraction are underutilized, particularly among elderly patients.
Caroline H. Garred +11 more
doaj +1 more source
The effect of eplerenone on adenosine formation in humans in vivo: a double-blinded randomised controlled study. [PDF]
PLoS ONE, 2014 It has been suggested that mineralocorticoid receptor antagonists have direct cardioprotective properties, because these drugs reduce mortality in patients with heart failure.
T N A van den Berg +5 more
doaj +1 more source